NFL Biosciences
Develops botanical drug candidates to treat smoking and alcohol addictions.
ALNFL | PA
Overview
Corporate Details
- ISIN(s):
- FR0014003XO1 (+1 more)
- LEI:
- 9695006VJWNTN4UNHA27
- Country:
- France
- Address:
- 199 RUE HELENE BOUCHER, 34170 CASTELNAU-LE-LEZ
- Website:
- https://www.nflbiosciences.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
NFL Biosciences is a biopharmaceutical company that develops botanical drug candidates for the treatment of addictions. The company's lead asset is NFL-101, an innovative drug candidate for smoking cessation derived from a nicotine-free protein extract of tobacco leaves. Its pipeline also includes NFL-301, a candidate aimed at reducing excessive alcohol consumption. NFL Biosciences operates with an outsourced research model, focusing on advancing its products through preclinical and clinical studies. The company's primary business strategy is to license its developed drug candidates to larger pharmaceutical companies for final commercialization.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-02-27 17:45 |
Changes in the governance of NFL Biosciences
|
English | 118.3 KB | ||
| 2023-02-22 18:00 |
NFL BIOSCIENCES: Inclusion of the first volunteer in the PRECESTO study
|
English | 139.7 KB | ||
| 2023-02-22 18:00 |
NFL BIOSCIENCES : 1ère inclusion de volontaire dans l’étude PRECESTO
|
French | 185.5 KB | ||
| 2023-02-20 17:45 |
NFL Biosciences obtient 1,7 million d’euros de financement « Avance Innovation …
|
French | 133.5 KB | ||
| 2023-02-20 17:45 |
NFL Biosciences receives € 1.7 million in « Avance Innovation » funding from Bp…
|
English | 129.6 KB | ||
| 2023-02-17 17:45 |
NFL : bilan semestriel du contrat de liquidité 2ème semestre 2022
|
English | 291.4 KB | ||
| 2023-02-02 17:45 |
NFL Biosciences collabore avec le CEA
|
French | 129.1 KB | ||
| 2023-02-02 17:45 |
NFL Biosciences collaborates with the CEA
|
English | 122.6 KB | ||
| 2023-01-31 07:45 |
NFL BIOSCIENCES : Très fort succès de l’augmentation de capital de NFL Bioscien…
|
French | 646.2 KB | ||
| 2023-01-31 07:45 |
NFL BIOSCIENCES: Very successful capital increase for NFL Biosciences with over…
|
English | 650.2 KB | ||
| 2023-01-30 18:26 |
NFL Biosciences launches a round of fundraising for approximately 2.5 million e…
|
English | 280.5 KB | ||
| 2023-01-30 17:58 |
NFL Biosciences lance une levée de fonds d’environ 2,5 millions d’euros
|
French | 198.9 KB | ||
| 2023-01-17 17:45 |
NFL Biosciences : Agenda de communication financière du 1er semestre 2023
|
French | 67.5 KB | ||
| 2023-01-17 17:45 |
NFL Biosciences: Financial calendar for the first half of 2023
|
English | 66.8 KB | ||
| 2023-01-11 17:45 |
NFL Biosciences reçoit une subvention conjointe de l’Etat Français et de la Rég…
|
French | 166.8 KB |
Automate Your Workflow. Get a real-time feed of all NFL Biosciences filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for NFL Biosciences
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for NFL Biosciences via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
